Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: An elevated expression of serum exosomal microRNA-191, − 21, −451a of pancreatic neoplasm is considered to be efficient diagnostic marker

Fig. 5

ExmiR-21 was a candidate prognostic factor for the survival of PC patients. The association between the three ExmiRs and the clinical outcomes in PC patients was evaluated. a, b PC patients were categorized into high- and low-ExmiR expression groups using the median miR value as the cut-off point. a The survival analysis by Kaplan-Meier method with a log-rank test was shown. The overall survival in the high-ExmiR-21 expression group was significantly shorter than that in the low-ExmiR-21 expression group (p = 0.0137, median OS of low-ExmiR-21 expression group: 846 days, median OS of high-ExmiR-21 expression group: 344 days), but ExmiR-191 and ExmiR-451a were not associated with the survival of PC patients. With regard to the other factors, UICC4 was a significant prognostic factor (p = 0.0232, median OS of UICC1,2,3: 1330 days, median OS of UICC4: 388.5 days). b Multivariate survival analysis using Cox’s proportional-hazards regression model was performed to assess the relationship between the overall survival and the following candidate prognostic factors that were found to be significant by the Kaplan–Meier method: UICC stage (stage IV) and ExmiR-21. UICC stage IV (hazard ratio: 3.902, 95% CI: 1.416–10.750) and the high expression of ExmiR-21 (hazard ratio: 4.071, 95%CI: 1.382–11.996) were identified as independent prognostic factors. c The association between the expressions of three ExmiRs and the clinical outcome of chemotherapy was also assessed. The ExmiR expressions were plotted and those median with interquartile range was also shown. The expression of ExmiR-21 and ExmiR-451a in the group with disease progression (PD) was significantly higher than in the group with complete response (CR), partial response (PR), or stable disease (SD) (p = 0.0221, p = 0.0429, respectively)

Back to article page